Regeneron’s Praluent sidekick nabs speedy FDA review, with February PDUFA date

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

Patients with high cholesterol from a rare genetic disorder struggle to keep their cholesterol levels in check, despite taking multiple lipid-busting drugs.

A new drug from Regeneron may change that—even for the most difficult-to-treat patients, and now it could see approval early next year after nabbing a speedy review.

MORE…